Last reviewed · How we verify
hydroxycontin/acetominophen
Hydrocodone (an opioid agonist) combined with acetaminophen provides analgesia through mu-opioid receptor activation and cyclooxygenase inhibition.
Hydrocodone (an opioid agonist) combined with acetaminophen provides analgesia through mu-opioid receptor activation and cyclooxygenase inhibition. Used for Moderate to moderately severe pain.
At a glance
| Generic name | hydroxycontin/acetominophen |
|---|---|
| Also known as | Norco |
| Sponsor | University of Rochester |
| Drug class | Opioid analgesic combination |
| Target | Mu-opioid receptor; cyclooxygenase (COX) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydrocodone binds to mu-opioid receptors in the central nervous system to reduce pain perception and transmission. Acetaminophen (paracetamol) inhibits cyclooxygenase enzymes and reduces prostaglandin synthesis, providing additional analgesic and antipyretic effects. The combination is used for moderate to moderately severe pain management.
Approved indications
- Moderate to moderately severe pain
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |